Home › Breast Cancer › Nebraska
Breast Cancer clinical trials in Nebraska
26 studies for Breast Cancer are looking for participants at sites in Nebraska.
Cities in Nebraska
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Nebraska Cancer Specialists, Omaha
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Sep 29, 2026 · NCT05827081ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Oncology Hematology West, Pc Dba Nebraska Cancer Specialists, Omaha
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07007559A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Cancer Partners of Nebraska ( Site 0068), Lincoln
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06966700A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Nebraska Cancer Specialists, Omaha
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07109726ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Oncology Hematology West, PC dba Nebraska Cancer Specialist, Grand Island
- Paradigm Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07173751The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Nebraska Medical Center Buffet Cancer Center, Omaha
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT04585750A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- NHO Revive Research Institute LLC, Lincoln
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Legacy, Omaha
- University of Nebraska Medical Center, Omaha
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06492616Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Nebraska Cancer Specialists, Omaha
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06982521A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Nebraska Cancer Specialists, Grand Island
- Nebraska Cancer Specialists, Omaha
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06790693Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Nebraska Cancer Specialists, Omaha
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06072612Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- CHI Health Saint Francis, Grand Island
- CHI Health Good Samaritan, Kearney
- Alegent Health Immanuel Medical Center, Omaha
- and 2 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Nebraska Medicine-Bellevue, Bellevue
- CHI Health Saint Francis, Grand Island
- Mary Lanning Memorial Hospital, Hastings
- and 7 more
RecruitingPhase 3
Ages 18 to 60 · Women · Updated Sep 2, 2026 · NCT05879926A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
- Research Site, Omaha
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07205822Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
- Nebraska Cancer Specialists, Omaha
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT07660055A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Cancer Partners of Nebraska, Lincoln
- Nebraska Cancer Specialists, Omaha
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07102381Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Nebraska Cancer Specialists, Omaha
- Nebraska Medicine - University of Nebraska Medical Center, Omaha
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Aug 6, 2026 · NCT05232916E-Mindfulness Approaches for Living After Breast Cancer
- CHI Health Good Samaritan, Kearney
RecruitingPhase 3
Ages 18 to 50 · All sexes · Updated Aug 4, 2026 · NCT06748222A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797Integrated Cancer Repository for Cancer Research
- Mary Lanning Healthcare, Morrison Cancer Center, Hastings
- Faith Regional Health Services, Carson Cancer Center, Norfolk
- Great Plains Regional Medical Center, North Platte
- and 3 more
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
- XCancer Omaha / Urology Cancer Center, Omaha
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT05283330ERAS Protocols in Breast Conserving Surgery
- University of Nebraska Medical Center, Omaha
Recruiting
Ages 19 and older · All sexes · Updated May 19, 2026 · NCT06938581De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Nebraska Medicine-Bellevue, Bellevue
- CHI Health Good Samaritan, Kearney
- Cancer Partners of Nebraska, Lincoln
- and 2 more
RecruitingPhase 3
Ages 50 to 70 · All sexes · Updated Apr 23, 2026 · NCT04852887Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- CHI Health Good Samaritan, Kearney
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 17, 2026 · NCT06418204SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Omaha
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
- Biotheryx Investigative Site, Omaha
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 6, 2025 · NCT06515470CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Nebraska Methodist, Omaha
RecruitingObservational study
Ages 18 and older · Women · Updated Jan 7, 2025 · NCT06230185From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.